News
-
-
-
COMMUNIQUÉ DE PRESSE
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
AdrenoMed AG receives FDA Fast Track designation for enibarcimab, a potential first treatment for septic shock addressing underlying pathophysiology. Precision medicine approach shows reduced mortality in clinical trials -
-
COMMUNIQUÉ DE PRESSE
Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer